These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34302920)

  • 41. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy.
    Choi C; Finlay DK
    Stem Cell Res Ther; 2021 Jun; 12(1):320. PubMed ID: 34090499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CAR-NK cells for cancer immunotherapy: recent advances and future directions.
    Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
    Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is Adoptive Cellular Therapy With Non-T-Cell Immune Effectors the Future?
    Ali AK; Tarannum M; Romee R
    Cancer J; 2021 Mar-Apr 01; 27(2):168-175. PubMed ID: 33750077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.
    Souza-Fonseca-Guimaraes F; Cursons J; Huntington ND
    Trends Immunol; 2019 Feb; 40(2):142-158. PubMed ID: 30639050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
    Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
    BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023.
    Li W; Feng J; Peng J; Zhang X; Aziz AUR; Wang D
    Hum Vaccin Immunother; 2024 Dec; 20(1):2415187. PubMed ID: 39414236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond CAR-T cells: Natural killer cells immunotherapy.
    Corral Sánchez MD; Fernández Casanova L; Pérez-Martínez A
    Med Clin (Barc); 2020 Feb; 154(4):134-141. PubMed ID: 31771858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
    Tanaka J
    Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natural killer cells in antitumour adoptive cell immunotherapy.
    Laskowski TJ; Biederstädt A; Rezvani K
    Nat Rev Cancer; 2022 Oct; 22(10):557-575. PubMed ID: 35879429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4.
    Jamali A; Hadjati J; Madjd Z; Mirzaei HR; Thalheimer FB; Agarwal S; Bonig H; Ullrich E; Hartmann J
    Front Immunol; 2020; 11():2028. PubMed ID: 32983147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.